Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Indications
Active ingredients of Incruse Ellipta 1
Incruse Ellipta 55 mcg (umeclidinium) inhalation powder.
Each single inhalation provides a delivered dose (the dose leaving the mouthpiece of the inhaler) of 55 micrograms (mcg) umeclidinium (equivalent to 65 mcg of umeclidinium bromide). This corresponds to a pre-dispensed dose of 62.5 mcg umeclidinium equivalent to 74.2 mcg umeclidinium bromide.
Incruse Ellipta Indication:
Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). 1
Reference:
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Incruse and Ellipta are registered trademarks of the GlaxoSmithKline Group of Companies
